US Patent 6887471 Method to inhibit T cell interactions with soluble B7
Patent 6887471 was granted and assigned to Bristol-Myers Squibb on May, 2005 by the United States Patent and Trademark Office.
All edits
Edits on 9 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 21 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 20 Oct, 2023
Golden AI
Edits made to:
Infobox (+13 properties)
Article (+295 characters)
Article
Patent abstract
This invention provides methods for regulating T cell interactions with B7 positive cells. Methods are provided for using B7 antigen, its fragments and derivatives reactive with CTLA4 receptor, to regulate CTLA4 positive T cell responses, and immune responses mediated by T cells.
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Jeffrey A. Ledbetter0
Nitin K. Damle0
Peter S. Linsley0
William Brady0
Date of Patent
May 3, 2005
0Patent Application Number
094546510
Date Filed
December 6, 1999
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 6887471 Method to inhibit T cell interactions with soluble B7
Find more entities like US Patent 6887471 Method to inhibit T cell interactions with soluble B7
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.